Hypera S.A. (HYPMY)

Market Cap	2.65B +24.1%
Revenue (ttm)	1.40B +3.4%
Net Income	217.02M -10.9%
EPS	0.34 -10.2%
Shares Out	n/a
PE Ratio	12.22
Forward PE	7.79
Dividend	0.15 (3.70%)
Ex-Dividend Date	Mar 2, 2026

Volume	10,407
Average Volume	22,818
Open	4.090
Previous Close	4.230
Day's Range	4.080 - 4.170
52-Week Range	3.170 - 5.500
Beta	0.20
RSI	43.83
Earnings Date	Mar 12, 2026

About Hypera

Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, pleased, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, Luna, moon, Lydian, macrodantin, MaxSulid, Milgamma, Mioflex – A, Nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, Softalm, Tacroz, Tinodin, Umma, an...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1999
• Employees: 10,481
• Stock Exchange: OTCMKTS
• Ticker Symbol: HYPMY

Financial Performance

In 2025, Hypera's revenue was 7.70 billion, an increase of 3.45% compared to the previous year's 7.44 billion. Earnings were 1.20 billion, a decrease of -10.86%.

Financial numbers in BRL